Two piperazine-containing 3,4-dihyroquinazolines (BK10007S/8S) have been synthesized, based on our previous work on the synthesis and antitumoral activity of 3,4-dihyroquinazolines. After evaluating them for T-type calcium channel blocking effect and in vitro anti-cancer effect, they were profiled for acute and repeat dose toxicity (40 mg/kg, 2 weeks) to BALB/c mice. BK10007S/8S were further in vivo evaluated against human pancreatic MIA PaCa-2 carcinoma in BALB/c nu/nu nude mice, which exhibited 54 and 61% tumor growth inhibition through 57-day oral administration of 2 mg/kg of body weight, respectively.
Introduction
Calcium is an important activator or inhibitor of numerous intracellular enzymes in the cytosol, organelles and nucleus. 1 Proliferation of tumors and non-tumor cells, is regulated, in part, by the second messenger calcium. 2, 3 Among several regulation mechanisms of calcium level, T-type (low voltage activated) calcium channels are well recognized to play a role in regulating calcium signaling during cell proliferation and differentiation in many tissues. 4, 5 Recently, the anticancer effects of a T-type Ca 2+ channel antagonists (or blockers) including mibefradil and pimozide on tumor cells in vivo have been reported by many researcher groups. 6, 7 Our group also have reported the identification of 3,4-dihydroquinazoline compound (KYS05090), which exhibits both selective/potent T-type calcium channel blocking effect and strong anti-cancer effect on A549 cancer cell lines comparable to doxorubicin and paclitaxel in vivo. [8] [9] [10] [11] [12] As a continuous work, two piperazine-containing 3,4-dihyroquinazolines (BK10007S/8S) have been synthesized and biologically evaluated for the growth inhibition effect against human pancreatic MIA PaCa-2 carcinoma xenografts, based on our previous work ( Figure 1 ). The results of these studies are reported herein.
Experimental
General Chemistry.
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C NMR spectra were recorded on a Varian Unity Plus 400 (400 MHz) spectrometer or a Bruker Avance-DRX 400 (400 MHz) spectrometer, using TMS as the internal standard; the chemical shifts (δ) are reported in parts per million and coupling constants (J) values are given in hertz (Hz). Signal multiplicities are represented by: s (singlet), d (doublet), t (triplet), q (quartet), br s (broad singlet), m (multiplet) and dd (double doublet). Low-resolution and High-resolution mass spectra (FABMS, FAB energy: 6 keV, Emission current: 5 mA, Acceleration voltage: 10 kV) were obtained using JMS-700 mass spectrometer (JEOL, JAPAN). The progress of all reactions was monitored using TLC on precoated silica gel plates (Merck Silica Gel 60 F 254 ). The chromatograms were viewed under UV light at 254 nm and 365 nm. For column chromatography, Merck Silica Gel (230-400 mesh ASTM) was used. Chemicals were purchased from Sigma-Aldrich, TCI, Alfa aesar, and Fluka.
Chemical Synthesis. Methyl trans-2-Aminocinnamate (3): To a solution of methyl trans-2-nitrocinnamate (500 mg, 1.41 mmol) in MeOH (20 mL) was added activated Zn powder (1.07 g, Figure 1 . Modification of KYS05090 into 1aS/1bS (BK10007S/8S). Methyl trans-2-(3-Biphenylureido)cinnamate (4): To a solution of biphenyl-4-carboxylic acid (5.00 g, 25.23 mmol) in distilled toluene (50 mL) was added 97% diphenyl phosphorazidate (DPPA) (7.13 mL, 31.70 mmol) and Et 3 N (5.89 mL, 53.33 mmol) at rt for Curtius rearrangement. The reaction mixture was stirred at rt for 3 h, further stirred at 100 o C for 3 h, followed by an addition of a solution of 3 (3.70 g, 20.88 mmol) in distilled toluene (100 mL) at rt. The reaction mixture was stirred for 12 h and concentrated under reduced pressure to give a solid, which was washed with MeOH (50 mL) to give desired urea (4) 
The reaction mixture containing ester (6) currents were evoked every 15 s by a 50 ms depolarizing voltage step from −100 mV to −30 mV. The molar concentrations of test compounds required to produce 50% inhibition of peak currents (IC 50 ) were determined from fitting raw data into dose-response curves. The current recordings were obtained using an EPC-9 amplifier and Pulse/Pulsefit software program (HEKA, Germany).
Acute Toxicity Study: BALB/c male mice (4 weeks old, 16-18 g) were purchased from NARA B/D (Pyeongtaek, Korea) and were acclimatized for 1 week before the experiment began (5 weeks old, 17.8-18.6 g). During this period and throughout the experiment the mice were housed in stainless cages, and were given access ad lib. to water and pellet chow (Pico Lab Rodent Diet 20, LabDiet, U.S.A.). The mice were kept under controlled conditions of temperature (23.1 ± 0.17 o C) and relative humidity (50.3 ± 1.14%), with a 12 h light/dark cycle. BK10007S/8S was suspended in saline(Dahan Pharm Co. Ltd., Korea) and given by gavages to three groups of two mice at doses of 0 (control: sterile distilled water) and 500 mg/kg body weight once daily. The animals were observed during 7 days. After this period of time, mice were weighed, killed and dissected to detect any macroscopic injuries of organs.
Repeat Dose Toxicity Study: BALB/c male mice (5 weeks old, 17-19 g) were purchased from NARA B/D (Pyeongtaek, Korea) and were acclimatized for 1 week before the experiment began (6 weeks old, 19.7-20.6 g). During this period and throughout the experiment the mice were housed in stainless cages, and were given access ad lib. to water and pellet chow (Pico Lab Rodent Diet 20, LabDiet, U.S.A.). The mice were kept under controlled conditions of temperature (23.1 ± 0.17 o C) and relative humidity (50.3 ± 1.14%), with a 12 h light/dark cycle. BK10007S/8S was dissolved in saline (Dahan Pharm Co. Ltd., Korea) and given by gavages to three groups of five mice at doses of 0 (control: sterile distilled water) and 40 mg/kg body weight for 2 weeks daily. The animals were observed during 15 days. After this period of time, mice were weighed, killed and dissected to detect any macroscopic injuries of hearts.
MTT Assay: The effect of BK10007S/8S on cell viability was assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in 3 replicates. Each cancer cells were seeded and incubated in 96-well, flatbottomed plates for 24 h and exposed to various concentrations of test agents dissolved in DMSO (final concentration, 0.1%) for 48 h. Controls received DMSO vehicle at a concentration equal to that in drug-treated cells. The medium was removed, replaced by 200 μL of 0.5 mg/mL MTT in 10% fetal bovine serum containing DMEM, and cells were incubated in the carbon dioxide incubator at 37 °C for 2 h. Supernatants were removed from the wells and the reduced MTT dye was solubilized in 100 μL/well DMSO. Absorbance at 570 nm was determined on a plate reader.
Antitumor Activity Using MIA PaCa-2 Xenograft Nude Mice. BALB/c nu/nu nude mice (6 weeks old) were purchased from Central Lab. Animal Inc. (Seoul, Korea) and were acclimatized for 1 or 2 weeks, before the experiment began. During this period and throughout the experiment the mice were housed in polysulfonate cages, and were given access ad libitum to water and pellet chow (TEKLAD CERTIFIED GLOBAL 18% PROTEIN RODENT DIET 2918C, Harlan TEKLAD, U.S.A.). The mice were kept under controlled conditions of temperature (20.7-22.0 o C) and relative humidity (26.7-49.9%), with a 12 h light/dark cycle. The MIA PaCa-2, which had been grown in Ham's F-12 Medium plus 10% FBS, were collected and reconstituted in Dulbecco's Phosphate Buffered Saline (D-PBS, pH 7.4). Approximately, 5-10 × 10 7 cells/mL were injected subcutaneously into the left flank region of the BALB/c nu/nu nude mice and the tumors were allowed to grow. After 2 weeks, tumors resulting after 2 weeks in donor animals were aseptically dissected and mechanically minced. Pieces of tumor tissue (3 mm At the end of experiment, all mice were weighed and sacrificed and their tumors were excised. Tumors were weighed and the mean tumor weight was calculated. The tumor growth inhibition rates (TGIR) were calculated as follows: Tumor growth inhibition rates, TGIR (%) = 100 × (C−T)/C, where T is the average tumor weight of the treated and C is the average tumor weight of the control.
Results and Discussion
Synthesis. We used a short synthetic route (see Scheme 1) that would allow the rapid and simultaneous optimization of the two variable points (P 1 and P
2
) and to produce two novel 3,4-dihydroquinazoline compounds (1aS/1bS). 12 The reduction of methyl trans-2-nitrocinnamate (2) with activated Zn and NH 4 Cl in MeOH afforded methyl trans-2-aminocinnamate (3), followed by an addition of biphenyl isocyanate, which was in situ prepared from the reaction of biphenyl-4-carboxylic acid and diphenyl phosphorazidate (DDPA) in the presence of TEA, produced methyl trans-2-(3-biphenylureido)cinnamate (4). 13 The dehydration of 4 with Ph 3 P·Br 2 and Et 3 N provided methyl trans-2-(3-biphenylcarbodiimido)cinnamate (5) Finally, salt formation to enhance aqueous solubility of compound 1aF and 1bF was carried out using 35% HCl in EtOAc to afford 1aS and 1bS (BK10007S/8S), respectively.
T-Type Channel Blocking Assay and Cytotoxicity Test. The channel blocking activity of BK10007F/8F was evaluated against HEK293 cells which stably express both T-type calcium channel Ca v 3.1 with α 1G subunit and potassium channel Kir2.1.
15 As shown in Table 1 , two compounds showed the similar T-type channel blocking activity (IC 50 value of ca. 0.3 μM; 10-fold active than mibefradil) but were slightly less active than KYS05090 in this work. These compounds were evaluated for cytotoxicity against five cancer cell lines, including human lung carcinoma (A549), human colon carcinoma (HT-29), human prostate carcinoma (DU145), human ovarian carcinoma (SK-O-V3) and human pancreatic carcinoma (MIA PaCa-2) using MTT assay.
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Cytotoxicity results are reported as IC 50 values in Table 1 . In SKOV3is the human ovarian carcinoma. g general, both BK10007F/8F showed the similar correlation between T-type channel blocking effect and cytotoxic effect, irrespective of a kind of carcinoma, compared to KYS05090 and mibefradil. In addition, they exhibited stronger cytotoxic activity than mibefradil, as expected based on T-type channel blocking effects. As like KYS05090, two compounds exhibited a range of cytotoxicity between 1.53 and 10.35 μM dependent on the tested carcinomas (HT-29 > MIA PaCa-2 > SKOV3 > A549 > DU145) as shown in Table 1 . Of them, BK10008F was as active as KYS05090 against five different tumor cell lines.
Toxicity Assay: For the oral administration, BK10007F/ 8F were converted into their HCl salt (BK10007S/8S) and profiled for their preliminary acute toxicity to BALB/c mice.
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Each compound was dissolved in saline (Dahan Pharm Co. Ltd., Korea) and given by gavages to three groups of two mice at doses of 0 (control: only sterile distilled water) and 500 mg/kg body weight once. The animals were observed and weighed every day during 7 days. First of all, it should be noted that all the mice given a single oral injection of BK10008S at the dose of 500 mg/kg of body weight showed no clinical signs and the mortality rate was zero. In the case of BK10007S, however, symptom such as loss of locomotor activity was observed. One animal was found dead six days after dosing and the mortality rate was 1/2 (50%). Meanwhile, a little of body weight loss was observed but recovered after 3 days on all alive mice against both compounds (data not shown). For repeat dose toxicity study, 18 BALB/c mice were again assigned to three groups (n = 5 per group) and mice in group 1 and 2 were orally given dose of 40 mg/kg of each compound, respectively, for 13 consecutive days. Mice in group 3 were administered vehicle (control: sterile distilled water) only. After this period of time, mice were weighed, killed and dissected to detect any macroscopic injuries of organs. As a result, no animal was found dead during 2-week study. No clinical sign was observed on any of the animals treated by each compound and control. No difference in body weight and relative food or water consumption between treatment groups was found (data not shown). As a result of dissection of all mice, finally, there was neither difference in organ weights between treatment groups nor macroscopic injuries of organs against each compound (Table 2) . With respect to calcium channel blockage-induced cardiac toxicity study, in particular, the histopathology of heart in mice (three animals per each group) exhibited no specific abnormal findings as shown in Figure 2 . Based on these overall data, BK10007S/8S are shown to be relatively less toxic compared to other cancer chemotherapeutic agents.
Antitumor Activity Assay. [19] [20] [21] Since BK10007S/8S was found to be potent cytotoxic against MIA PaCa-2, we evaluated the in vivo antitumor activity of BK10007S/8S against MIA PaCa-2 (human pancreatic carcinoma) xenografts in BALB/c nu/nu nude mice model in comparison with doxorubicin as positive control. MIA PaCa-2 (5-10 × 10 7 cells/mL) were injected subcutaneously (s.c.) into the left flank region of BALB/c nu/nu nude mice and the tumors were allowed to grow. When tumor nodules were clearly visible (ca. 100 mm 3 ) after 14 days, each compound with 2 mg/kg dose in saline was orally (po) administered once per day for consecutive 57 days and doxorubicin with 2 mg/kg dose in physical normal saline was administered through intraperitoneal (ip) injection twice per week during 37 days because all mice treated with doxorubicin were killed within 37 days after administration. Tumor lengths and widths were measured once in 4 days using a caliper and tumor volume was calculated as 1/2 × length × width × height until animal sacrifice. The results are documented in Figure 3 and Table  3 . Figure 3 (a) displays the effects of BK10007S/8S on tumor growth in nude mice presented as tumor volume over time.
The rates of tumor volume increment in mouse model with both BK10007S/8S-treated groups were remarkably slower than that of control group (vehicle only) and comparable to that of doxorubicin during 33 days. Meanwhile, all mice treated with doxorubicin were killed within 37 days after administration, which showed the high toxicity of doxorubicin. With respect to the tumor volume, BK10007S/8S exhibited ca. 2.8-fold efficacy than control at 57 th day as shown in Figure 3(a) . At the end of experiment, all mice were weighed and sacrificed, and their tumors were excised. Tumors were weighed and the mean tumor weight was calculated. The tumor growth inhibition rates (TGIR) were calculated as follows: Tumor growth inhibition rates (TGIR, %) = 100 × (C−T)/C, where T is the average tumor weight of the treated and C is the average tumor weight of the control (vehicle only). The results presented in Figure 3 (b) and Table 3 showed that showed that BK10007S/8S through oral administration of 2 mg/kg of body weight exhibited good experimental therapeutic efficacy in vivo against MIA PaCa-2 xenograft in mice by 54 and 61%, respectively, compared with control alone. With respect to body weight loss related with its chronic toxicity, there was no statistical difference between average total body weights in mice treated with BK10008S and vehicle (control). However, BK10007S-treated group exhibited slightly body weight loss compared to BK10008S-treated group as shown in Figure 3 (c), which implies relatively stronger toxicity of BK10007S than BK10008S. This body weight result is somewhat consistent with the acute toxicity data of BK10007S/8S above. These overall results revealed that BK10008S may have a tumor suppressor function in human pancreatic cancer cells and could be a promising treatment in oral pancreatic cancer chemotherapy.
Conclusions
As a continuous part of our research for anti-tumoral agents using T-type calcium channel blockers, two novel piperazine-containing 3,4-dihyroquinazolines (BK10007S/ 8S) were selected from the modification of our lead compound KYS05090 and evaluated for their biological effects such as channel blocking effect, cytotoxicity, toxicity, and growth inhibition against human pancreatic MIA PaCa-2 carcinoma in BALB/c nu/nu nude mice. Based on these comprehensive data, BK10008S could be a promising chemotherapeutic ) were injected subcutaneously into the left flank of nude mice. Mice were separated into four groups (n = 6 per each group). After 14 days when tumor nodules were clearly visible, control and test compounds were administered for 57 days. All animals were euthanized after 57 days and the tumors were excised and measured. Data points represent a means ± S.E.; (a) tumor volumes in mice of each group; (b) tumor weights in mice of each group measured on the last day of the experiment; (c) body weights in mice of each group during the experiment. agent for the pancreatic cancer treatment and thus its intensive preclinical experiments are in progress using high dosage (40 mg/kg body weight) and will be announced in the future.
